What Colorado Can Learn from the Research Triangle About Sector Specialization
Colorado deployed $7.4 billion in venture capital in 2025. The Research Triangle in North Carolina deployed $2.4 billion. By any measure of total venture capital, Colorado wins that comparison easily. However, there is one ranking where North Carolina sits at the top and Colorado does not, and it tells an important story about how innovation ecosystems generate lasting economic value.
North Carolina's Research Triangle
The Research Triangle is the number one per capita life sciences venture capital market in the United States. It achieved that distinction on roughly a third of Colorado's total venture capital base. This success is the result of decades of deliberate sector concentration anchored by world-class research institutions, a dense network of specialized investors, and a regional identity that has made life sciences its defining economic narrative. When a biotech founder is choosing where to locate or spinout, the Research Triangle is oftentimes top of mind.
The Regional Venture Capital Comparison Report, based on venture capital data covering 2020 through 2025, draws an explicit lesson from that contrast. Ecosystems that concentrate around distinct sector strengths attract outsized investment relative to their size. Colorado has four sectors that could generate equivalent national identity: Life Sciences, Quantum & Photonics, Space Technology and Advanced Sensing. Each of those sectors already has meaningful venture activity. Space technology alone drew $3.4 billion in Colorado between 2021 and 2025.
The main question is whether Colorado will build the sector-specific capital infrastructure to match its research and talent assets. Right now, the stage mix tilts heavily toward later rounds. Of the $7.4 billion deployed in Colorado in 2025, roughly 68% went to later-stage venture. That structure reflects strength in mature companies, but a thinner pipeline of early-stage capital that sector-focused investors typically provide. The Research Triangle's success in life sciences did not happen because later-stage investors chose it. It happened because early-stage, sector-specialized capital was present and patient enough to build companies to the point where those larger investors followed.
The comparison with the Twin Cities reinforces the same point from a different angle. Minnesota's market is smaller in absolute terms, with $1.1 billion invested across 172 deals in 2025, but it maintains a deep concentration in medical devices and healthcare technology that anchors its ecosystem across market cycles. Even as total capital contracted from its 2021 peak of $2.9 billion, the Twin Cities sustained a consistent deal pipeline because its sector identity is strong enough to retain specialized investors through downturns.
For Innosphere and the NSF ASCEND Engine, this analysis sharpens a strategic priority that is already embedded in the region's work. The ASCEND Engine's focus on advanced sensing and computation for environmental decision-making is a deliberate attempt to concentrate Colorado and Wyoming's research activity around problems where the region has genuine competitive advantage. The venture capital data suggests that kind of specialization, sustained and amplified over time, is exactly what converts regional research strength into durable investor identity.
Colorado has the science, the talent, and the sector alignment with national priorities. Building the capital architecture to match is the work ahead. The full Regional Venture Capital Comparison Report is available at innosphere.org or through this link.
